Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 16;10:238. doi: 10.1038/s41398-020-00923-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — a Compared to vehicle (Veh, square), dulaglutide (Dul, triangle) reduced ethanol intake in female rats during 5 weeks of active treatment (sessions 1–15). Ethanol consumption returned to baseline after treatment was terminated (session 16–33, area marked with grey). b Dulaglutide decreased ethanol preference, but no differences were noted during the treatment discontinuation period. c Water intake was higher in dulaglutide-treated rats, but this difference did not persist after discontinuation of treatment. d Dulaglutide treatment increased total fluid intake, which was sustained during the treatment discontinuation period. e Dulaglutide had an overall effect on food intake. However, this difference was not evident following treatment discontinuation. f Active dulaglutide treatment had no effect on body weight gain. Body weight gain was overall higher in rats previously treated with dulaglutide. Data are presented as mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001: interaction effects after repeated measures two-way ANOVA. ^•P < 0.05, ^••P < 0.001, ^•••P < 0.001: Bonferroni post-hoc analysis. Session 0 represent the baseline values.